BN Business News
Add your company to Business Communicator →

Business · 17/11/20261 min read

Opinion/decision on a Paediatric investigation plan (PIP): Besponsa, Inotuzumab ozogamicin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: P/0079/2023

EDITORIAL ILLUSTRATIONBBusinessBN
Illustration generated by Business News; it is not a source photograph.

Summary

Opinion/decision on a Paediatric investigation plan (PIP): Besponsa, Inotuzumab ozogamicin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: P/0079/2023

Original source language: EMA — Paediatric Investigation PlansOpen original release →

Explore insights

Business insights →